442 related articles for article (PubMed ID: 21459094)
21. Dynamic Phenotypic Transition of Breast Cancer Cells
Oku Y; Nishiya N; Tsuda K; Shibazaki M; Maesawa C; Uehara Y
Anticancer Res; 2017 Apr; 37(4):1793-1797. PubMed ID: 28373443
[TBL] [Abstract][Full Text] [Related]
22. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Yashiro M; Nishii T; Hasegawa T; Matsuzaki T; Morisaki T; Fukuoka T; Hirakawa K
Br J Cancer; 2013 Nov; 109(10):2619-28. PubMed ID: 24129235
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
Kurtzberg LS; Battle T; Rouleau C; Bagley RG; Agata N; Yao M; Schmid S; Roth S; Crawford J; Krumbholz R; Ewesuedo R; Yu XJ; Wang F; Lavoie EJ; Teicher BA
Mol Cancer Ther; 2008 Oct; 7(10):3212-22. PubMed ID: 18852125
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
27. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
Arcaroli JJ; Powell RW; Varella-Garcia M; McManus M; Tan AC; Quackenbush KS; Pitts TM; Gao D; Spreafico A; Dasari A; Touban BM; Messersmith WA
Mol Oncol; 2012 Jun; 6(3):370-81. PubMed ID: 22521243
[TBL] [Abstract][Full Text] [Related]
28. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
[TBL] [Abstract][Full Text] [Related]
30. Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note.
James MI; Howells LM; Karmokar A; Higgins JA; Greaves P; Cai H; Dennison A; Metcalfe M; Garcea G; Lloyd DM; Berry DP; Steward WP; Brown K
PLoS One; 2015; 10(2):e0117776. PubMed ID: 25658706
[TBL] [Abstract][Full Text] [Related]
31. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
Su P; Yang Y; Wang G; Chen X; Ju Y
Int J Oncol; 2018 Sep; 53(3):1343-1353. PubMed ID: 29956726
[TBL] [Abstract][Full Text] [Related]
32. Impact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies.
Giolito MV; Bodoirat S; La Rosa T; Reslinger M; Guardia GDA; Mourtada J; Claret L; Joung A; Galante PAF; Penalva LOF; Plateroti M
Cell Death Dis; 2024 May; 15(5):306. PubMed ID: 38693105
[TBL] [Abstract][Full Text] [Related]
33. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
[TBL] [Abstract][Full Text] [Related]
35. [Antitumor effect of camptothecin analog on liver metastatic model of human colon cancer in nude mice].
Takiguchi S; Shimazoe T; Kono A
Gan To Kagaku Ryoho; 1994 Apr; 21(5):705-8. PubMed ID: 8154898
[No Abstract] [Full Text] [Related]
36. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
37. 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
Denise C; Paoli P; Calvani M; Taddei ML; Giannoni E; Kopetz S; Kazmi SM; Pia MM; Pettazzoni P; Sacco E; Caselli A; Vanoni M; Landriscina M; Cirri P; Chiarugi P
Oncotarget; 2015 Dec; 6(39):41706-21. PubMed ID: 26527315
[TBL] [Abstract][Full Text] [Related]
38. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
39. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
[TBL] [Abstract][Full Text] [Related]
40. RECQL5 is an important determinant for camptothecin tolerance in human colorectal cancer cells.
Wang X; Lu X; Zhou G; Lou H; Luo G
Biosci Rep; 2011 Oct; 31(5):363-9. PubMed ID: 21210765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
